FORT LEE, N.J., April 29, 2025--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for ...
Subducted and melanotic cells in the eyes of patients with advanced age-related macular degeneration (AMD) derive from two distinct retinal pigment epithelium (RPE) phenotypes, research shows.
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — It is feasible and safe to surgically implant an investigational human embryonic stem cell derived RPE ...
Patient with Dry Age-Related Macular Degeneration Injected with 100,000 Retinal Pigment Epithelial Cells at Wills Eye Institute in Philadelphia <0> Investors:CEOcast, Inc.James Young, ...
Researchers at Anglia Ruskin University (ARU), led by Professor Barbara Pierscionek, have been working on a method to successfully cultivate retinal pigment epithelial (RPE) cells that remain healthy ...
The National Eye Institute has awarded Jackson Laboratory Professor Patsy Nishina, Ph.D., and Associate Professor Gregory Carter, Ph.D., a four-year grant totaling $2,414,304 to study diseases of the ...
ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD
<0> Investors:CEOcast, Inc.James Young, 212-732-4300orPress:ACT Corporate CommunicationsBill Douglass, 646-450-3615or:Russo PartnersMartina Schwarzkopf, Ph.D., 212 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results